FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200154472> ?p ?o ?g. }

• W4200154472 endingPage "254" @default.
• W4200154472 startingPage "253" @default.
• W4200154472 abstract "Immune checkpoint inhibitors (ICI) have revolutionized the treatment of advanced NSCLC. While preclinical models have suggested a role for the use of ICIs in EGFR mutant (mt) lung cancer, results from clinical trials evaluating programmed cell death (ligand) protein 1 (PD (L)1) inhibitors in patients with EGFR mt NSCLC have been disappointing [ 1 Zhang N. Zeng Y. Du W. Zhu J. Shen D. Liu Z. Huang J.A. The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer. Int. J. Oncol. 2016; 49: 1360-1368 Crossref PubMed Scopus (182) Google Scholar , 2 Akbay E.A. Koyama S. Carretero J. Altabef A. Tchaicha J.H. Christensen C.L. Mikse O.R. Cherniack A.D. Beauchamp E.M. Pugh T.J. Wilkerson M.D. Fecci P.E. Butaney M. Reibel J.B. Soucheray M. Cohoon T.J. Janne P.A. Meyerson M. Hayes D.N. Shapiro G.I. Shimamura T. Sholl L.M. Rodig S.J. Freeman G.J. Hammerman P.S. Dranoff G. Wong K.-K. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013; 3: 1355-1363 Crossref PubMed Scopus (930) Google Scholar , 3 Lisberg A. Cummings A. Goldman J.W. Bornazyan K. Reese N. Wang T. Coluzzi P. Ledezma B. Mendenhall M. Hunt J. Wolf B. Jones B. Madrigal J. Horton J. Spiegel M. Carroll J. Gukasyan J. Williams T. Sauer L. Wells C. Hardy A. Linares P. Lim C. Ma L. Adame C. Garon E.B. A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naive Patients With Advanced NSCLC. J. Thoracic Oncol. Official Publication Int. Assoc. Study Lung Cancer. 2018; 13: 1138-1145 Abstract Full Text Full Text PDF PubMed Scopus (306) Google Scholar , 4 Hellmann M.D. Rizvi N.A. Goldman J.W. Gettinger S.N. Borghaei H. Brahmer J.R. Ready N.E. Gerber D.E. Chow L.Q. Juergens R.A. Shepherd F.A. Laurie S.A. Geese W.J. Agrawal S. Young T.C. Li X. Antonia S.J. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017; 18: 31-41 Abstract Full Text Full Text PDF PubMed Scopus (683) Google Scholar , 5 Yang J.C. Gadgeel S.M. Sequist L.V. Wu C.L. Papadimitrakopoulou V.A. Su W.C. Fiore J. Saraf S. Raftopoulos H. Patnaik A. Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation. J. Thoracic Oncol. Official Publication Int. Assoc. Study Lung Cancer. 2019; 14: 553-559 Abstract Full Text Full Text PDF PubMed Scopus (92) Google Scholar , 6 Oxnard G.R. Yang J.C. Yu H. Kim S.W. Saka H. Horn L. Goto K. Ohe Y. Mann H. Thress K.S. Frigault M.M. Vishwanathan K. Ghiorghiu D. Ramalingam S.S. Ahn M.J. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. Ann. Oncol. 2020; 31: 507-516 Abstract Full Text Full Text PDF PubMed Scopus (182) Google Scholar , 7 Langer C.J. Gadgeel S.M. Borghaei H. Papadimitrakopoulou V.A. Patnaik A. Powell S.F. Gentzler R.D. Martins R.G. Stevenson J.P. Jalal S.I. Panwalkar A. Yang J.C. Gubens M. Sequist L.V. Awad M.M. Fiore J. Ge Y. Raftopoulos H. Gandhi L. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016; 17: 1497-1508 Abstract Full Text Full Text PDF PubMed Scopus (1035) Google Scholar , 8 Soo R.A. Lim S.M. Syn N.L. Teng R. Soong R. Mok T.S.K. Cho B.C. Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions. Lung cancer (Amsterdam, Netherlands). 2018; 115: 12-20 Abstract Full Text Full Text PDF PubMed Scopus (118) Google Scholar , 9 Qiao M. Jiang T. Liu X. Mao S. Zhou F. Li X. Zhao C. Chen X. Su C. Ren S. Zhou C. Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?, Journal of thoracic oncology : official publication of the International Association for the Study of. Lung Cancer. 2021; 16: 1267-1288 Google Scholar ]. However, the role of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitors has not been extensively studied in EGFR mt NSCLC. In a phase I study reported upon in this issue of Lung Cancer, Riudavets et al. sought to evaluate the safety and efficacy of tremelimumab, a CTLA-4 inhibitor, in combination with gefitinib, an EGFR-TKI, in patients with EGFR mt advanced NSCLC after progression on a first-line EGFR-TKI. Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trialLung CancerVol. 166PreviewSensitizing mutations in the epidermal growth factor receptor (EGFR) are present in 15% of Caucasian and nearly 50% of Asian patients with non-small cell lung cancer (NSCLC) [1–2], with small in-frame deletions of exon 19 or substitution of a leucine for an arginine at codon 858 (p.L858R) in exon 21 representing up to 85% of them. Full-Text PDF" @default.
• W4200154472 created "2021-12-31" @default.
• W4200154472 creator A5059052850 @default.
• W4200154472 creator A5060287300 @default.
• W4200154472 creator A5069849827 @default.
• W4200154472 creator A5076473304 @default.
• W4200154472 creator A5078435189 @default.
• W4200154472 date "2022-04-01" @default.
• W4200154472 modified "2023-09-25" @default.
• W4200154472 title "What is the current role of immunotherapy in EGFR mutant advanced NSCLC?" @default.
• W4200154472 cites W2123918574 @default.
• W4200154472 cites W2494860457 @default.
• W4200154472 cites W2529904548 @default.
• W4200154472 cites W2560704457 @default.
• W4200154472 cites W2575507470 @default.
• W4200154472 cites W2769570103 @default.
• W4200154472 cites W2777461561 @default.
• W4200154472 cites W2803642760 @default.
• W4200154472 cites W2805354595 @default.
• W4200154472 cites W2889653218 @default.
• W4200154472 cites W2903379674 @default.
• W4200154472 cites W3001408868 @default.
• W4200154472 cites W3168951757 @default.
• W4200154472 cites W3171073565 @default.
• W4200154472 cites W3181561651 @default.
• W4200154472 cites W3202671569 @default.
• W4200154472 cites W3204288837 @default.
• W4200154472 doi "https://doi.org/10.1016/j.lungcan.2021.12.001" @default.
• W4200154472 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35031176" @default.
• W4200154472 hasPublicationYear "2022" @default.
• W4200154472 type Work @default.
• W4200154472 citedByCount "0" @default.
• W4200154472 crossrefType "journal-article" @default.
• W4200154472 hasAuthorship W4200154472A5059052850 @default.
• W4200154472 hasAuthorship W4200154472A5060287300 @default.
• W4200154472 hasAuthorship W4200154472A5069849827 @default.
• W4200154472 hasAuthorship W4200154472A5076473304 @default.
• W4200154472 hasAuthorship W4200154472A5078435189 @default.
• W4200154472 hasConcept C121608353 @default.
• W4200154472 hasConcept C126322002 @default.
• W4200154472 hasConcept C143998085 @default.
• W4200154472 hasConcept C2776256026 @default.
• W4200154472 hasConcept C2777701055 @default.
• W4200154472 hasConcept C502942594 @default.
• W4200154472 hasConcept C71924100 @default.
• W4200154472 hasConceptScore W4200154472C121608353 @default.
• W4200154472 hasConceptScore W4200154472C126322002 @default.
• W4200154472 hasConceptScore W4200154472C143998085 @default.
• W4200154472 hasConceptScore W4200154472C2776256026 @default.
• W4200154472 hasConceptScore W4200154472C2777701055 @default.
• W4200154472 hasConceptScore W4200154472C502942594 @default.
• W4200154472 hasConceptScore W4200154472C71924100 @default.
• W4200154472 hasLocation W42001544721 @default.
• W4200154472 hasLocation W42001544722 @default.
• W4200154472 hasOpenAccess W4200154472 @default.
• W4200154472 hasPrimaryLocation W42001544721 @default.
• W4200154472 hasRelatedWork W2009226744 @default.
• W4200154472 hasRelatedWork W2786497694 @default.
• W4200154472 hasRelatedWork W2937519691 @default.
• W4200154472 hasRelatedWork W3137670083 @default.
• W4200154472 hasRelatedWork W3171615116 @default.
• W4200154472 hasRelatedWork W3184088343 @default.
• W4200154472 hasRelatedWork W3207563288 @default.
• W4200154472 hasRelatedWork W3215044659 @default.
• W4200154472 hasRelatedWork W3217115064 @default.
• W4200154472 hasRelatedWork W4283212020 @default.
• W4200154472 hasVolume "166" @default.
• W4200154472 isParatext "false" @default.
• W4200154472 isRetracted "false" @default.
• W4200154472 workType "article" @default.